Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valganciclovir + mycophenolate
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
valganciclovir + mycophenolate is a combination therapeutic regimen evaluated in the PROTECT clinical trial, sponsored by the University of Bologna, for the prevention of cardiac allograft vasculopathy (CAV) and cytomegalovirus (CMV) infection in heart transplant recipients. Valganciclovir is an antiviral prodrug of ganciclovir that inhibits viral DNA polymerase, thereby preventing CMV replication. Mycophenolate (typically administered as mycophenolate mofetil) is an immunosuppressant that acts as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme essential for the de novo synthesis of guanosine nucleotides in T and B lymphocytes. This specific combination is studied to compare universal prophylaxis against pre-emptive therapy strategies to determine their impact on coronary intimal thickening and long-term graft survival.
- Brand names
- ValcyteCellCeptMyfortic
- Other names
- valganciclovir and mycophenolate mofetil
02
Targets
CMV DNA polymerase (Human cytomegalovirus DNA polymerase)
Beyond the preview
Go deeper on valganciclovir + mycophenolate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valganciclovir + mycophenolate.